Cargando…
Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers
Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1) antibodies (Abs) and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) Abs, have been widely administered for not only advanced melanoma, but also various non-melanoma skin cancers. Since profiles of tumor-infiltr...
Autor principal: | Fujimura, Taku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8999844/ https://www.ncbi.nlm.nih.gov/pubmed/35409404 http://dx.doi.org/10.3390/ijms23074044 |
Ejemplares similares
-
Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers
por: Fujimura, Taku, et al.
Publicado: (2020) -
Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma
por: Fujimura, Taku, et al.
Publicado: (2022) -
Editorial: Recent Developments in Therapies and Diagnostic Tools for Melanoma and Non-melanoma Skin Cancer
por: Fujimura, Taku, et al.
Publicado: (2020) -
Immunotherapy for Non-melanoma Skin Cancer
por: Shalhout, Sophia Z., et al.
Publicado: (2021) -
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023)